title: Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy.
abstract: OBJECTIVE
  Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the epidermal growth factor family, is a target for ovarian cancer therapy. The present study investigated the administration schedule of BK-UM, an anticancer agent targeting HB-EGF.
  
  
  METHODS
  The ovarian cancer cell line, RMG-I, was injected subcutaneously into five-week-old female nude mice. The BK-UM was administered intraperitoneally, using three administration schedules with different doses. The tumor volume was calculated every week. Statistical significance was assessed using the Mann-Whitney U-test.
  
  
  RESULTS
  At doses >0.1 mg/kg, BK-UM displayed significant antitumor effects, although the antitumor effects and body weights of mice did not significantly differ by dose or by three different administration schedules. At a dose <0.1 mg/kg, however, BK-UM had little inhibitory effect on tumor growth.
  
  
  CONCLUSIONS
  Daily administration of BK-UM, which has a potentially dose-dependent antitumor effect, may be the optimal schedule for clinical application.
authors: Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan Department of Biochemistry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan Department of Central Research Institute for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan.
authors: Sung Ouk
authors: SO
authors: Nam
authors: Department of Biochemistry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan Department of Central Research Institute for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan.
authors: Fusanori
authors: F
authors: Yotsumoto
authors: Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan Department of Biochemistry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan Department of Central Research Institute for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan.
authors: Kohei
authors: K
authors: Miyata
authors: Medical Center for Translational Research, Osaka University Hospital, Osaka, Japan.
authors: Yuki
authors: Y
authors: Suzaki
authors: Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors: Hiroshi
authors: H
authors: Yagi
authors: Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, Kagawa, Japan.
authors: Takashi
authors: T
authors: Odawara
authors: Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, Kagawa, Japan.
authors: Sadao
authors: S
authors: Manabe
authors: Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, Kagawa, Japan.
authors: Toyokazu
authors: T
authors: Ishikawa
authors: Department of Biochemistry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
authors: Masahide
authors: M
authors: Kuroki
authors: Department of Cell Biology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
authors: Eisuke
authors: E
authors: Mekada
authors: Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan Department of Central Research Institute for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan smiya@cis.fukuoka-u.ac.jp.
authors: Shingo
authors: S
authors: Miyamoto
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000494:pharmacology*; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D005260:Female; D066257:Heparin-binding EGF-like Growth Factor; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology*; D051379:Mice; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D001426:Bacterial Proteins; C587883:HBEGF protein, human; C587884:Hbegf protein, mouse; D066257:Heparin-binding EGF-like Growth Factor; D036341:Intercellular Signaling Peptides and Proteins; C028581:CRM197 (non-toxic variant of diphtheria toxin)
keywords: BK-UM (CRM197); HB-EGF; ovarian cancer; preclinical study